Browsing category:

Anti-Retroviral / Anti-HIV


As an antiviral medication used to treat cytomegalovirus retinitis, also known as CMV in patients infected with the HIV virus, the current Cidofovir shortage is alarming (see the FDA Cidofovir shortage posting). Administered as an injectable treatment intravenously, the dosing of Cidofovir can take up to six hours to complete. The treatment of 75 mg/ml[…]

Read More

The end of October 2013 saw a nod from the FDA given to Gilead’s New Drug Application for Sofosbuvir. As a greatly needed treatment for hepatitis C Sofosbuvir has proven to be effectual and tolerable in a number of studies. Sofosbuvir is marketed by Gilead Science, Inc. and is clearly set up for success in[…]

Read More

The current shortage of Acyclovir, CAS number 59277-98-3, is of great concern to the medical community. As a valued and integral treatment for encephalitis, the shortage of Acyclovir for compounding pharmacies has created an urgent need for both patients and practitioners. The August 27, 2013 issue of the Neurology journal cautioned healthcare professionals to be[…]

Read More

A report in the Journal of the American Medical Association on August 28, 2013 offered exciting news for patients with Hepatitis C. A phase 2 trial of the drugs Sofosbuvir and Ribavirin revealed that this curing combination gives patients with Hepatitis C a viable treatment that is tolerable and effectively clears the virus.  The study[…]

Read More

On August 12, 2013 Viiv Healthcare proudly announced the FDA approval of the integrase inhibitor, Dolutegravir to combat the HIV virus. Known as the brand name Tivicay, Dolutegravir is typically used in combination with other antiretroviral medications to treat patients with AIDS, ages twelve and older. With many patients living longer while being infected with[…]

Read More

Breaking news in the pharmaceutical world made headlines on June 12, 2013, when the Centers for Disease Control and Prevention revealed a study touting the prophylactic benefit of Tenofovir. Coined pre-exposure prophylaxis or PrEP, this study advocating the use of Tenofovir as an interventional pre-treatment was published in the Lancet in mid- June of 2013.[…]

Read More

As a successful nonnucleoside reverse transcriptase inhibitor, Etravirine, CAS number 269055-15-4 is also known as the brand name Intelence. With the patent for Intelence set to expire for Janssen on November 5, 2019, additional research and development offering generic formulations of this effectual treatment for AIDS is sure to proliferate. Last year Etravirine was approved[…]

Read More

On March 6, 2013 The Physician’s Weekly reported that a new Tenofovir Pro-Drug had less potential for bone and kidney toxicity, but still remained efficacious as a treatment for both Hepatitis and HIV infection. The findings were revealed at the 20th Conference on Retroviruses and Opportunistic Infections 2013 in Atlanta, Georgia. Tenofovir is a vastly[…]

Read More

The recent headlines proclaiming a cure for a Mississippi baby who had been exposed to the HIV virus which causes AIDS have captivated the world. This child was born to an HIV positive mother who had not received any prenatal care to reduce the transmission of the virus. Dr. Hannah Gay, who treated the baby,[…]

Read More

Atazanavir Sulfate, CAS No: 229975-97-7 is also known as the antiretroviral medication Reyataz. With the patent for Reyataz expiring on June 20, 2017 research and development teams are currently working on the development of a generic version of this vital drug. Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection, atazanavir[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service